keyword
MENU ▼
Read by QxMD icon Read
search

Mannitol cystic fibrosis

keyword
https://www.readbyqxmd.com/read/30107772/management-of-bronchiectasis-in-adults
#1
Simone K Visser, Peter Bye, Lucy Morgan
Once neglected in research and underappreciated in practice, there is renewed interest in bronchiectasis unrelated to cystic fibrosis. Bronchiectasis is a chronic lung disease characterised by chronic cough, sputum production and recurrent pulmonary exacerbations. It is diagnosed radiologically on high resolution computed tomography chest scan by bronchial dilatation (wider than the accompanying artery). The causes of bronchiectasis are diverse and include previous respiratory tract infections, chronic obstructive pulmonary disease, asthma, immunodeficiency and connective tissue diseases...
August 20, 2018: Medical Journal of Australia
https://www.readbyqxmd.com/read/29886096/a-new-therapeutic-avenue-for-bronchiectasis-dry-powder-inhaler-of-ciprofloxacin-nanoplex-exhibits-superior-ex-vivo-mucus-permeability-and-antibacterial-efficacy-to-its-native-ciprofloxacin-counterpart
#2
The-Thien Tran, Celine Vidaillac, Hong Yu, Valerie F L Yong, Dan Roizman, Ravishankar Chandrasekaran, Albert Y H Lim, Teck Boon Low, Gan Liang Tan, John A Abisheganaden, Mariko Siyue Koh, Jeanette Teo, Sanjay H Chotirmall, Kunn Hadinoto
Non-cystic fibrosis bronchiectasis (NCFB) characterized by permanent bronchial dilatation and recurrent infections has been clinically managed by long-term intermittent inhaled antibiotic therapy among other treatments. Herein we investigated dry powder inhaler (DPI) formulation of ciprofloxacin (CIP) nanoplex with mannitol/lactose as the excipient for NCFB therapy. The DPI of CIP nanoplex was evaluated against DPI of native CIP in terms of their (1) dissolution characteristics in artificial sputum medium, (2) ex vivo mucus permeability in sputum from NCFB and healthy individuals, (3) antibacterial efficacy in the presence of sputum against clinical Pseudomonas aeruginosa strains (planktonic and biofilm), and (4) cytotoxicity towards human lung epithelial cells...
August 25, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29626547/repurposing-excipients-as-active-inhalation-agents-the-mannitol-story
#3
Sandra D Anderson, Evangelia Daviskas, John D Brannan, Hak Kim Chan
The story of how we came to use inhaled mannitol to diagnose asthma and to treat cystic fibrosis began when we were looking for a surrogate for exercise as a stimulus to identify asthma. We had proposed that exercise-induced asthma was caused by an increase in osmolarity of the periciliary fluid. We found hypertonic saline to be a surrogate for exercise but an ultrasonic nebuliser was required. We produced a dry powder of sodium chloride but it proved unstable. We developed a spray dried preparation of mannitol and found that bronchial responsiveness to inhaling mannitol identified people with currently active asthma...
April 5, 2018: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/29593709/hypertonic-saline-suppresses-nadph-oxidase-dependent-neutrophil-extracellular-trap-formation-and-promotes-apoptosis
#4
Ajantha Nadesalingam, Jacky H K Chen, Armin Farahvash, Meraj A Khan
Tonicity of saline (NaCl) is important in regulating cellular functions and homeostasis. Hypertonic saline is administered to treat many inflammatory diseases, including cystic fibrosis. Excess neutrophil extracellular trap (NET) formation, or NETosis, is associated with many pathological conditions including chronic inflammation. Despite the known therapeutic benefits of hypertonic saline, its underlying mechanisms are not clearly understood. Therefore, we aimed to elucidate the effects of hypertonic saline in modulating NETosis...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29424930/inhaled-mannitol-for-cystic-fibrosis
#5
REVIEW
Sarah J Nevitt, Judith Thornton, Clare S Murray, Tiffany Dwyer
BACKGROUND: Several agents are used to clear secretions from the airways of people with cystic fibrosis. Mannitol increases mucociliary clearance, but its exact mechanism of action is unknown. The dry powder formulation of mannitol may be more convenient and easier to use compared with established agents which require delivery via a nebuliser. Phase III trials of inhaled dry powder mannitol for the treatment of cystic fibrosis have been completed and it is now available in Australia and some countries in Europe...
February 9, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29235345/mucus-and-cell-penetrating-nanoparticles-embedded-in-nano-into-micro-formulations-for-pulmonary-delivery-of-ivacaftor-in-patients-with-cystic-fibrosis
#6
Barbara Porsio, Emanuela Fabiola Craparo, Nicolò Mauro, Gaetano Giammona, Gennara Cavallaro
Here, mucus-penetrating nanoparticles (NPs) for pulmonary administration of ivacaftor in patients with cystic fibrosis (CF) were produced with the dual aim of enhancing ivacaftor delivery to the airway epithelial cells, by rapid diffusion through the mucus barrier, and at the same time, promoting ivacaftor lung cellular uptake. Pegylated and Tat-decorated fluorescent nanoparticles (FNPs) were produced by nanoprecipitation, starting from two synthetic copolymers, and showed nanometric sizes (∼70 nm), a slightly negative ζ potential, and high cytocompatibility toward human bronchial epithelium cells...
January 10, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28397992/mucoactive-agents-for-chronic-non-cystic-fibrosis-lung-disease-a-systematic-review-and-meta-analysis
#7
REVIEW
Benjamin J Tarrant, Caitlin Le Maitre, Lorena Romero, Ranjana Steward, Brenda M Button, Bruce R Thompson, Anne E Holland
Inhaled mucoactive agents are used in respiratory disease to improve mucus properties and enhance secretion clearance. The effect of mannitol, recombinant human deoxyribonuclease/dornase alfa (rhDNase) and hypertonic saline (HS) or normal saline (NS) are not well described in chronic lung conditions other than cystic fibrosis (CF). The aim of this review was to determine the benefit and safety of inhaled mucoactive agents outside of CF. We searched Medline, Embase, CINAHL and CENTRAL for randomized controlled trials investigating the effects of mucoactive agents on lung function, adverse events (AEs), health-related quality of life (HRQOL), hospitalization, length of stay, exacerbations, sputum clearance and inflammation...
August 2017: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/28258928/inhaled-dry-powder-mannitol-in-children-with-cystic-fibrosis-a-randomised-efficacy-and-safety-trial
#8
RANDOMIZED CONTROLLED TRIAL
K De Boeck, E Haarman, J Hull, L C Lands, A Moeller, A Munck, J Riethmüller, H Tiddens, S Volpi, J Leadbetter, B Charlton, A Malfroot
INTRODUCTION: Inhaled mannitol has beneficial effects on lung function, mucociliary clearance, quality of life and sputum properties. This trial examined the efficacy of inhaled mannitol in children with cystic fibrosis (CF). METHODS: The efficacy of inhaled mannitol in children with CF aged 6-17years was assessed in a phase 2, randomised, placebo-controlled crossover study. Subjects were randomly assigned to mannitol 400mg every 12h or matching placebo for 8weeks, followed by an 8week washout and an 8week period with the alternate treatment...
May 2017: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://www.readbyqxmd.com/read/27879162/polyanion-tobramycin-nanocomplexes-into-functional-microparticles-for-the-treatment-of-pseudomonas-aeruginosa-infections-in-cystic-fibrosis
#9
Emanuela F Craparo, Barbara Porsio, Domenico Schillaci, Maria G Cusimano, Dario Spigolon, Gaetano Giammona, Gennara Cavallaro
AIM: Efficacy of antibiotics in cystic fibrosis (CF) is compromised by the poor penetration through mucus barrier. This work proposes a new 'nano-into-micro' approach, used to obtain a combinatorial effect: achieve a sustained delivery of tobramycin and overcome mucus barrier. METHODS: Mannitol microparticles (MPs) were loaded with a tobramycin polymeric nanocomplex and characterized in presence of CF artificial mucus. RESULTS & DISCUSSION: MPs are able to alter the rheological properties of CF artificial mucus, enhancing drug penetration into it and allowing a prolonged drug release...
January 2017: Nanomedicine
https://www.readbyqxmd.com/read/27563742/the-advantages-of-adding-hyaluronic-acid-or-mannitol-to-hypertonic-saline-inhalation-treatment-in-cystic-fibrosis
#10
Clizia Cazzarolli, Chiara Tartali, Ugo Pradal
No abstract text is available yet for this article.
April 2017: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/27449745/development-of-inhalable-hyaluronan-mannitol-composite-dry-powders-for-flucytosine-repositioning-in-local-therapy-of-lung-infections
#11
G Costabile, I d'Angelo, R d'Emmanuele di Villa Bianca, E Mitidieri, B Pompili, P Del Porto, L Leoni, P Visca, A Miro, F Quaglia, F Imperi, R Sorrentino, F Ungaro
Flucytosine (5-fluorocytosine, 5-FC) is a fluorinated analogue of cytosine currently approved for the systemic treatment of fungal infections, which has recently demonstrated a very promising antivirulence activity against the bacterial pathogen Pseudomonas aeruginosa. In this work, we propose novel inhalable hyaluronic acid (HA)/mannitol composite dry powders for repositioning 5-FC in the local treatment of lung infections, including those affecting cystic fibrosis (CF) patients. Different dry powders were produced in one-step by spray-drying...
September 28, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/27043279/dornase-alfa-for-cystic-fibrosis
#12
REVIEW
Connie Yang, Mark Chilvers, Mark Montgomery, Sarah J Nolan
BACKGROUND: Dornase alfa is currently used as a mucolytic to treat pulmonary disease (the major cause of morbidity and mortality) in cystic fibrosis. It reduces mucus viscosity in the lungs, promoting improved clearance of secretions. This is an update of a previously published review. OBJECTIVES: To determine whether the use of dornase alfa in cystic fibrosis is associated with improved mortality and morbidity compared to placebo or other medications that improve airway clearance, and to identify any adverse events associated with its use...
April 4, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26867712/inhaled-mannitol-bronchitol-for-cystic-fibrosis
#13
REVIEW
Sarah J Nolan, Judith Thornton, Clare S Murray, Tiffany Dwyer
No abstract text is available yet for this article.
March 2016: Paediatric Respiratory Reviews
https://www.readbyqxmd.com/read/26698651/new-commercially-available-igg-kits-and-time-resolved-fluorometric-ige-assay-for-diagnosis-of-allergic-bronchopulmonary-aspergillosis-in-patients-with-cystic-fibrosis
#14
Coralie Barrera, Bénédicte Richaud-Thiriez, Steffi Rocchi, Bénédicte Rognon, Sandrine Roussel, Frédéric Grenouillet, Audrey Laboissière, Jean-Charles Dalphin, Gabriel Reboux, Laurence Millon
Allergic bronchopulmonary aspergillosis (ABPA) is difficult to diagnose; diagnosis relies on clinical, radiological, pathological, and serological criteria. Our aim was to assess the performance of two new commercially available kits and a new in-house assay: an Aspergillus fumigatus enzyme-linked immunosorbent assay (ELISA) IgG kit (Bordier Affinity Products), an Aspergillus Western blotting IgG kit (LDBio Diagnostics), and a new in-house time-resolved fluorometric IgE assay (dissociation-enhanced lanthanide fluorescent immunoassay, or DELFIA) using recombinant proteins from an Aspergillus sp...
December 23, 2015: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/26634006/hot-topics-from-the-assemblies
#15
(no author information available yet)
Mannitol improves mucus clearance in non-cystic fibrosis (CF) bronchiectasis and improves mucus clearance and pulmonary function test results in patients with CF. It is not clear to what extent inhaled mannitol has an impact on exacerbation rates and quality of life in patients with non-CF bronchiectasis.
September 2015: Breathe
https://www.readbyqxmd.com/read/26510267/pseudomonas-aeruginosa-displays-an-altered-phenotype-in-vitro-when-grown-in-the-presence-of-mannitol
#16
J E Moore, J C Rendall, D G Downey
D-mannitol has been approved in dry powder formulation as an effective antimucolytic agent in patients with cystic fibrosis. What is not known is the effect of adding a metabolisable sugar on the biology of chronic bacterial pathogens in the CF lung. Therefore, a series of simple in vitro experiments were performed to examine the effect of adding D-mannitol on the phenotype of the CF respiratory pathogens Pseudomonas aeruginosa and Burkholderia cenocepacia. Clinical isolates (n = 86) consisting of P. aeruginosa (n = 51), B...
2015: British Journal of Biomedical Science
https://www.readbyqxmd.com/read/26506004/mannitol-does-not-enhance-tobramycin-killing-of-pseudomonas-aeruginosa-in-a-cystic-fibrosis-model-system-of-biofilm-formation
#17
Katherine E Price, Giulia Orazi, Kathryn L Ruoff, Wesley P Hebert, George A O'Toole, Paul Mastoridis
Cystic Fibrosis (CF) is a human genetic disease that results in the accumulation of thick, sticky mucus in the airways, which results in chronic, life-long bacterial biofilm infections that are difficult to clear with antibiotics. Pseudomonas aeruginosa lung infection is correlated with worsening lung disease and P. aeruginosa transitions to an antibiotic tolerant state during chronic infections. Tobramycin is an aminoglycoside currently used to combat lung infections in individuals with CF. While tobramycin is effective at eradicating P...
2015: PloS One
https://www.readbyqxmd.com/read/26451533/inhaled-mannitol-for-cystic-fibrosis
#18
REVIEW
Sarah J Nolan, Judith Thornton, Clare S Murray, Tiffany Dwyer
BACKGROUND: Several agents are used to clear secretions from the airways of people with cystic fibrosis. Inhaled dry powder mannitol is now available in Australia and some countries in Europe. The exact mechanism of action of mannitol is unknown, but it increases mucociliary clearance. Phase III trials of inhaled dry powder mannitol for the treatment of cystic fibrosis have been completed. The dry powder formulation of mannitol may be more convenient and easier to use compared with established agents which require delivery via a nebuliser...
October 9, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26412676/importance-of-topology-for-glycocluster-binding-to-pseudomonas-aeruginosa-and-burkholderia-ambifaria-bacterial-lectins
#19
Caroline Ligeour, Lucie Dupin, Anthony Angeli, Gérard Vergoten, Sébastien Vidal, Albert Meyer, Eliane Souteyrand, Jean-Jacques Vasseur, Yann Chevolot, François Morvan
Pseudomonas aeruginosa (PA) and Burkholderia ambifaria (BA) are two opportunistic Gram negative bacteria and major infectious agents involved in lung infection of cystic fibrosis patients. Both bacteria can develop resistance to conventional antibiotherapies. An alternative strategy consists of targeting virulence factors in particular lectins with high affinity ligands such as multivalent glycoclusters. LecA (PA-IL) and LecB (PA-IIL) are two tetravalent lectins from PA that recognise galactose and fucose respectively...
December 14, 2015: Organic & Biomolecular Chemistry
https://www.readbyqxmd.com/read/26340361/overcoming-barriers-in-pseudomonas-aeruginosa-lung-infections-engineered-nanoparticles-for-local-delivery-of-a-cationic-antimicrobial-peptide
#20
Ivana d'Angelo, Bruno Casciaro, Agnese Miro, Fabiana Quaglia, Maria Luisa Mangoni, Francesca Ungaro
Cationic antimicrobial peptides (CAMPs) are very promising in the treatment of multi-drug resistant Pseudomonas aeruginosa lung infections experienced by cystic fibrosis (CF) patients. Nevertheless, there is an urgent need of inhalable formulations able to deliver the intact CAMP in conductive airways and to shield its interactions with airway mucus/bacterial biofilm, thus enhancing CAMP/bacteria interactions. Along these lines, the aim of this work was the design and development of nano-embedded microparticles (NEM) for sustained delivery of CAMPs in the lung...
November 1, 2015: Colloids and Surfaces. B, Biointerfaces
keyword
keyword
160612
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"